- Home
- OMCC vs FBIO Comparison
OMCC vs FBIO Comparison
Compare OMCC & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCC
- FBIO
- Stock Information
- Founded
- OMCC 1985
- FBIO 2006
- Country
- OMCC United States
- FBIO United States
- Employees
- OMCC N/A
- FBIO N/A
- Industry
- OMCC
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- OMCC
- FBIO Health Care
- Exchange
- OMCC NYSE
- FBIO Nasdaq
- Market Cap
- OMCC 43.4M
- FBIO 39.4M
- IPO Year
- OMCC N/A
- FBIO N/A
- Fundamental
- Price
- OMCC $6.09
- FBIO $1.57
- Analyst Decision
- OMCC
- FBIO Strong Buy
- Analyst Count
- OMCC 0
- FBIO 4
- Target Price
- OMCC N/A
- FBIO $17.00
- AVG Volume (30 Days)
- OMCC 16.2K
- FBIO 601.4K
- Earning Date
- OMCC 11-13-2024
- FBIO 11-14-2024
- Dividend Yield
- OMCC N/A
- FBIO N/A
- EPS Growth
- OMCC N/A
- FBIO N/A
- EPS
- OMCC N/A
- FBIO N/A
- Revenue
- OMCC $22,185,000.00
- FBIO $81,501,000.00
- Revenue This Year
- OMCC N/A
- FBIO N/A
- Revenue Next Year
- OMCC N/A
- FBIO $81.63
- P/E Ratio
- OMCC N/A
- FBIO N/A
- Revenue Growth
- OMCC N/A
- FBIO 31.51
- 52 Week Low
- OMCC $5.29
- FBIO $1.36
- 52 Week High
- OMCC $7.55
- FBIO $4.43
- Technical
- Relative Strength Index (RSI)
- OMCC N/A
- FBIO 42.37
- Support Level
- OMCC N/A
- FBIO $1.41
- Resistance Level
- OMCC N/A
- FBIO $1.64
- Average True Range (ATR)
- OMCC 0.00
- FBIO 0.12
- MACD
- OMCC 0.00
- FBIO -0.02
- Stochastic Oscillator
- OMCC 0.00
- FBIO 27.59
About OMCC OLD MARKET CAPITAL CORPORATION
Old Market Capital Corp formerly Nicholas Financial Inc is a specialized consumer finance company. It is engaged in acquiring and servicing automobile finance installment contracts for purchases of used and new automobiles and light trucks. It also originates direct consumer loans and sells consumer-finance-related products. The majority of its revenue comes from Interest and fee income.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.